Verrica Pharmaceuticals Inc. has announced the entry into the sixth amendment and waiver to its Credit Agreement originally dated July 26, 2023. This amendment, effective June 10, 2025, involves a collaboration with OrbiMed Royalty & Credit Opportunities IV, LP, acting as both lender and administrative agent. Under the terms of this amendment, the lenders have agreed to waive specific covenants, particularly the requirement for no "going concern" qualification in the company's financial statements for certain upcoming periods. In return, Verrica Pharmaceuticals has agreed to pay an amendment fee of $110,465.12. The terms of the original Credit Agreement remain largely unchanged except for the provisions detailed in the Sixth Amendment. The company plans to file this amendment as an exhibit in its upcoming quarterly report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.